REGENERON PHARMACEUTICALS, INC. 8-K

What Happened

• On January 30, 2026, Regeneron Pharmaceuticals, Inc. filed an 8-K (Item 2.02) to announce its financial and operating results for the quarter and year ended December 31, 2025. The company furnished a press release reporting those quarterly and full-year results as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: January 30, 2026.
• Reporting period: quarter and full year ended December 31, 2025.
• Press release furnished to the SEC as Exhibit 99.1 (included with the 8-K).
• Report signed on behalf of Regeneron by Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary.

Why It Matters

• This 8-K notifies investors that Regeneron has released its quarterly and full-year earnings and operating results — information that typically includes revenue, net income, and operational metrics that can affect the stock.
• Retail investors should read the referenced press release (Exhibit 99.1) and any subsequent SEC filings (e.g., the Form 10-K) for the detailed numbers, trends, and management commentary before making investment decisions.